close

Вход

Забыли?

вход по аккаунту

?

927

код для вставкиСкачать
2239
Errata
In the article by Truica et al. (Truica CI, Hansen CH, Garvin DF, Meehan KR.
Idiopathic giant cell myocarditis after autologous hematopoietic stem cell transplantation and interleukin-2 immunotherapy: a case report. Cancer 1998;83(6):
1231– 6), Figures 1 through 3 were printed in black and white and important details
were lacking. The figures are printed below and on the following page in color. The
publisher regrets the error.
FIGURE 1.
This section of myocardium contains a diffuse infiltrate of
lymphocytes, histiocytes, plasma cells, and multinucleated giant cells (H & E,
original magnification ⫻400).
© 1998 American Cancer Society
2240
CANCER November 15, 1998 / Volume 83 / Number 10
FIGURE 2 (Above).
Immunoperoxidase staining for CD68 and muscle
specific actin in shown. The multinucleated giant cell is CD68 positive (A) and
muscle specific actin negative (B) (original magnification ⫻400).
FIGURE 3. In situ end-labeling for fragmented DNA is shown. The nuclei of
cells with fragmented DNA stained purple, and the rest stained green. A
longitudinal section of myocardium shows myocardial cells with apoptosis
(original magnification ⫻400).
Errata
In the article by Bartlett et al. (Bartlett DL, Buell JF, Libutti SK, Reed E. Lee KB, Figg
WE, Venzon DJ. Alexander HR. A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 1998;83(6):1251– 61), Table 4 was missing critical information. The table is printed below. The authors regret the error.
TABLE 4
Pharmacology by Dose Level
CDDP/TNF
dose level
100/0
150/0
200/0
250/0
300/0
350/0
250/0.1
250/0.3
n
AUC total CDDP
perfusate/plasma
(␮g-min/mL)
AUC ultrafiltrate CDDP
perfusate/plasma
(␮g-min/mL)
AUC TNF
perfusate plasma
(ng-min/mL)
Tumor CDDP levels
(ng/mg tissue)
3
3
3
4
3
2
7
2
1742 ⫾ 549/35 ⫾ 19
1753 ⫾ 333/79 ⫾ 28
5143 ⫾ 1009/115 ⫾ 20
4227 ⫾ 1306/211 ⫾ 150
4347 ⫾ 563/498 ⫾ 84
4100 ⫾ 8/685 ⫾ 173
3505 ⫾ 1206/327 ⫾ 78
3195 ⫾ 1298/526 ⫾ 102
683 ⫾ 102/33 ⫾ 6
730 ⫾ 225/67 ⫾ 32
1035 ⫾ 218/74 ⫾ 26
1997 ⫾ 762/162 ⫾ 109
3264 ⫾ 1490/240 ⫾ 23
678 ⫾ 482/369 ⫾ 144
2497 ⫹ 657/186 ⫾ 52
2127 ⫾ 1099/226 ⫾ 18
—
—
—
—
—
—
10,835 ⫾ 3725/1.8 ⫾ 1.3
16,387 ⫾ 11,538/4.1 ⫾ 4.9
1.04 ⫾ 1.36 (n ⫽ 2)
1.37 ⫾ 1.16 (n ⫽ 3)
0.08 (n ⫽ 1)
13.5 ⫾ 12.0 (n ⫽ 2)
9.2 ⫾ 3.3 (n ⫽ 2)
12 ⫾ 12.7 (n ⫽ 2)
18.9 ⫾ 13.6 (n ⫽ 6)
3.5 ⫾ 2.0 (n ⫽ 2)
CDDP: cisplatin; TNF: tumor necrosis factor; AUC: area under the curve.
a
Data are reported for mean values ⫾ standard deviation.
In the article by Sukpanichnant et al. (Sukpanichnant S, Sonakul D, Piankijagum A,
Wanachiwanawin W, Veerakul G, Mahasandana C, et al. Malignant lymphoma in
Thailand: changes in the frequency of malignant lymphoma determined from a
histopathologic and immunophenotypic analysis of 425 cases at Siriraj Hospital.
Cancer 1998;83(6):1197–204), the authors have subsequently discovered that one
case of hairy cell leukemia should be deleted from the study because the entity is
not included in the miscellaneous group according to the Working Formulation for
clinical usage.
The deletion of this single case produced minor changes in calculated percentages.
Please contact the authors directly for the specific changes. The corresponding
author is Sanya Sukpanichnant, MD, Department of Pathology, Faculty of Medicine,
Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
The authors regret the error.
2241
Документ
Категория
Без категории
Просмотров
2
Размер файла
618 Кб
Теги
927
1/--страниц
Пожаловаться на содержимое документа